A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India

Allergan250 enrolled

Overview

This is a Post-Marketing Surveillance study in India to evaluate safety and efficacy of BOTOX® (Botulinum Toxin Type A) in the treatment of patients with urinary incontinence due to neurogenic detrusor overactivity or overactive bladder.

Study Type

OBSERVATIONAL

Enrollment

250

Conditions

Urinary Incontinence Overactive Bladder

Interventions

botulinum toxin Type ABIOLOGICAL

Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with urinary incontinence due to NDO or OAB treated with BOTOX® as per local standard of care in clinical practice. Exclusion Criteria: * None

Locations (12)

NU Hospitals

Padmanabha Nagar, Banglore, India

Bodyline Hospitals

Ahmedabad, Gujarat, India

Fortis Hospitals

Bengaluru, Karnataka, India

Outcomes

Primary Outcomes

Change from the baseline value of the International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF)

Time frame: at up to 4 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.